throbber
Cytokine & Growth Factor Reviews 23 (2012) 85–97
`
`Contents lists available at SciVerse ScienceDirect
`
`Cytokine & Growth Factor Reviews
`
`j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / c y t o g f r
`
`Survey
`
`Plasticity and cross-talk of Interleukin 6-type cytokines
`
`Christoph Garbers a, Heike M. Hermanns b, Fred Schaper c, Gerhard Mu¨ ller-Newen d, Joachim Gro¨ tzinger e,
`Stefan Rose-John e, Ju¨ rgen Scheller a,*
`
`a Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich-Heine University, Du¨sseldorf, Germany
`b Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine, University of Wu¨rzburg, Wu¨rzburg, Germany
`c Institute of Biology, Otto-von-Guericke-University, Magdeburg, Germany
`d Institute of Biochemistry and Molecular Biology, RWTH Aachen University, Aachen, Germany
`e Institute of Biochemistry, Christian-Albrechts-University, Olshausenstrabe 40, Kiel, Germany
`
`A R T I C L E
`
`I N F O
`
`A B S T R A C T
`
`Article history:
`Available online 15 May 2012
`
`Keywords:
`Interleukin-6
`Cross-talk
`Plasticity
`Signal transduction
`
`Contents
`
`Interleukin (IL)-6-type cytokines are critically involved in health and disease. The duration and strength
`of IL-6-type cytokine-mediated signaling is tightly regulated to avoid overshooting activities. Here,
`molecular mechanisms of inter-familiar cytokine cross-talk are reviewed which regulate dynamics and
`strength of IL-6 signal transduction. Both plasticity and cytokine cross-talk are significantly involved in
`pro- and anti-inflammatory/regenerative properties of IL-6-type cytokines. Furthermore, we focus on IL-
`6-type cytokine/cytokine receptor plasticity and cross-talk exemplified by the recently identified
`composite cytokines IL-30/IL-6R and IL-35, the first inter-familiar IL-6/IL-12 family member. The
`complete understanding of the intra- and extracellular cytokine networks will aid to develop novel tailor-
`made therapeutic strategies with reduced side effects.
`
` 2012 Elsevier Ltd. All rights reserved.

`
`1.
`2.
`3.
`4.
`5.
`6.
`7.
`8.
`9.
`
`Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`IL-6-type cytokines, their receptors and main signaling pathways . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Plasticity and intra-familiar cross-talk of IL-6-type cytokines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`IL-35: the first shared IL-6/IL-12 family cytokine
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Inter-familiar cross-talk of the major early pro-inflammatory cytokines IL-6, IL-1 and TNFa. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Inter-familiar cross-talk between IL-6 and glucocorticoids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Inter-familiar cross-talk of IL-6 and G-protein-coupled receptors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Inter-familiar cross-talk of IL-6 and receptor tyrosine kinase signaling: taming insulin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Conclusions and future directions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
`
`85
`86
`88
`88
`90
`91
`92
`93
`94
`94
`94
`
`1. Introduction
`
`Cytokines are released by a huge variety of different cell types
`and generally act locally as auto- and paracrine factors. Their
`functions are
`involved
`in multiple physiological processes,
`including differentiation, proliferation, migration and apoptosis
`of their target cells [1–4]. Therefore, their ability to signal and
`activate other cells must be tightly regulated, since uncoordinated
`
`* Corresponding author. Tel.: +49 211 8112724; fax: +49 211 8112726.
`E-mail address: jscheller@uni-duesseldorf.de (J. Scheller).
`
` 2012 Elsevier Ltd. All rights reserved.
`1359-6101/$ – see front matter
`http://dx.doi.org/10.1016/j.cytogfr.2012.04.001
`

`
`cytokine signaling correlates with several pathophysiological
`states,
`including acute and chronic
`inflammatory diseases,
`neoplastic disorders, cancer and autoimmune diseases [5].
`In a simplistic view, any cytokine binds to a unique cytokine
`receptor pair, leading to the activation of intracellular signaling
`pathways on target cells. Receptor proteins and major signaling
`pathways of IL-6-type cytokines have been investigated over the
`last two decades (reviewed
`in [6,7]). Most data have been
`generated under controlled experimental conditions using
`defined cell lines stimulated with single cytokines. This reduc-
`tionistic experimental approach was extremely successful to
`identify the basic signaling pathways, but when combined,
`
`Lassen - Exhibit 1019, p. 1
`
`

`

`86
`
`C. Garbers et al. / Cytokine & Growth Factor Reviews 23 (2012) 85–97
`
`cytokines, hormones and other stimuli might have additive,
`synergistic or antagonistic effects, a phenomenon referred to as
`cross-talk. In vivo, cross-talk is more likely the rule but the
`exception, since each cell has constantly to react to a variety of
`factors at almost
`the same
`time.
`In
`line with
`this,
`the
`reductionistic experimental approach was recently challenged
`by several studies dealing with cytokine cross-talk. Importantly, it
`was found that cytokine cross-talk does not only exist at the level
`of interfering signal transduction pathways but also at the level of
`cytokines and their receptors. Here, plasticity within cytokine/
`cytokine receptor binding sites allows, to a certain extent, that a
`cytokine can use different receptor combinations. Very little is
`known about how a cytokine discriminates between different
`options, but we feel that this decision will be driven by affinity and
`receptor abundance.
`In this review, we focus on intra- and interfamiliar IL-6-type
`cytokine cross-talk. Intra-familiar IL-6-type cytokine cross-talk
`was described for several cytokines of the IL-6-type family and is
`based on binding site/interface plasticity of the cytokine to its
`receptor(s).
`Inter-familiar
`IL-6-type cross-talk was
`recently
`highlighted by studies elucidating the connection between IL-6
`and IL-1 signaling pathways. Sections discussing the current
`knowledge of IL-6-type cytokine cross-talk are preceded by an
`introduction to IL-6-type cytokines, their basic receptor composi-
`tion and major signaling pathways. We hope that this review leads
`to a better perception of the emerging world of cytokine/cytokine
`receptor cross-talk and plasticity not only within the IL-6-type
`family of cytokines.
`
`2. IL-6-type cytokines, their receptors and main signaling
`pathways
`
`All cytokines of the IL-6 family belong to the four-helical bundle
`cytokine family. These proteins share little sequence homology
`and were only recognized to be related by prediction and analysis
`of their protein fold [8]. Interestingly, the four-helical bundle fold
`with an up–up–down–down topology has so far only been found in
`mediator proteins such as interleukins, cytokines and growth
`factors [9].
`Cytokines signal through a specific combination of b-receptors
`with supporting a-receptors to increase target cell specificity and
`to prevent unwanted cellular activation. Cytokine receptors for
`cytokines of the
`IL-6
`family belong to the
`immunoglobulin
`superfamily [8,9]. Two different types of cytokine receptors are
`distinguished. Short chain a-receptors consisting of 3 immuno-
`globulin-/fibronectin-like domains bind their cognate ligands and
`present
`these
`to
`long chain b-receptors consisting of 5–8
`immunoglobulin (Ig)-like/fibronectin-like domains. These
`long
`chain b-receptors
`form homo- or heterodimers and
`initiate
`intracellular signaling [10]. All cytokines of the IL-6 family signal
`via the long chain signal transducing b-receptor glycoprotein
`130 kDa (gp130). As shown in Fig. 1A, IL-6 and IL-11 use a
`homodimer of gp130 whereas all other members of the IL-6 family
`use heterodimers of gp130 and one of the other b-receptors
`leukemia inhibitory factor receptor (LIFR), oncostatin M receptor
`(OSMR) or WSX-1 (IL-27R). A somewhat special case
`is the
`cytokine IL-31, which binds to a heterodimer of OSMR and the IL-
`31 receptor A (IL-31RA) also known as gp130-like protein (GPL)
`[11]. Some cytokines need additional non-signaling a-receptors to
`bind to their b-receptors (Fig. 1A). These a-receptors are either
`membrane-bound such as IL-6R for IL-6, IL-11R for IL-11 and ciliary
`neurotrophic factor receptor (CNTFR) for CNTF or cardiotrophin-
`like cytokine (CLC), or are soluble such as Epstein-Barr virus
`induced gene 3 (EBI3) for IL-30 (p28) to form the composite
`cytokine IL-27 [12]. The cytokines OSM, LIF and IL-31 do not need
`
`an additional a-receptor. It is still not clear if cardiotrophin-1 (CT-
`1) needs an a-receptor [13] (Fig. 1A).
`Except for IL-31, all IL-6-type cytokines bind to the b-receptor
`gp130, indicating a high degree of binding site plasticity within
`gp130 and the respective cytokines. Crystal structures of the
`cytokine/receptor complex have been solved for IL-6 in complex
`with IL-6R and gp130 and for the CBM of gp130 in complex to LIF
`[14,15] (Fig. 1B). Binding of IL-6-type cytokines is mainly mediated
`by ionic and hydrophobic interactions [16], however, inspection of
`the electrostatic surface potential of site II of IL-6, CNTF, LIF and
`OSM (constituted by helices A and C) and the cytokine binding
`module (CBM) of gp130 (domains 2 and 3) reveals almost no
`similarity (Fig. 1B). Per definition, site II and site III are binding sites
`within the cytokine which interact with the b-receptors, whereas
`site I is the binding site for the a-receptor (Fig. 1C and D).
`Therefore, the interaction between site II of the respective cytokine
`and the CBM of gp130 has been described as a chemical plasticity
`resulting in a slightly different orientation of the cytokine and the
`CBM of gp130 [17].
`Gp130 is expressed on all cells whereas the other receptor
`subunits show a more restricted expression profile [5]. Since no
`cytokine of the IL-6 family can signal via gp130 alone, it follows
`that the expression of the additional a- and b-receptor subunits
`determines whether a given cell will be responsive to the cytokine
`[5]. This is illustrated by the two cytokines IL-6 and IL-11, both
`signaling through a homodimer of gp130 plus additional specific
`a-receptors (Fig. 1A). In this case, expression of the a-receptors IL-
`6R and IL-11R determines responsiveness of a target cell. The IL-6R
`is mainly expressed on hepatocytes and some leukocyte popula-
`tions, including macrophages, monocytes, neutrophils, B- and T-
`cells [18], whereas the IL-11R has been detected on lymphocytes,
`B-cells, macrophages, endothelial cells, hematopoietic cells and
`osteoclasts [19]. These data, however, did not include quantitative
`analysis of a-receptor expression, and it is not possible to predict, if
`a cell, expressing both a-receptors, reacts more efficiently to IL-6
`or IL-11. Moreover, comprehensive data covering all receptors and
`cell types are still missing, and it is so far unclear whether cells can
`adapt their receptor expression profile,
`for example during
`pathophysiologic conditions. Examples of activation-dependent
`receptor presentation were shown for CD4 T cells, which lose
`membrane-bound IL-6R during activation via a process called
`ectodomain shedding mediated by ADAM proteases [20,21] and for
`hepatic cells or fibroblasts, which internalize gp130 rapidly in
`response to IL-1b [22].
`In case of IL-6, an additional mechanism for cellular activation
`has been recognized. Besides the membrane-bound
`IL-6R, a
`soluble form of the IL-6R (sIL-6R) is present in many body fluids.
`The sIL-6R is generated by limited proteolysis by ADAM10 or
`ADAM17 of the membrane-bound IL-6R and to a lesser extent by
`translation from an alternatively spliced mRNA in which the exon
`coding for the transmembrane region has been skipped [18]. The
`sIL-6R can still bind its ligand IL-6 and the complex of IL-6 and sIL-
`6R interacts with gp130 and thus activates cells which do not
`express IL-6R and are therefore unresponsive to IL-6 alone. This
`signaling paradigm has been called IL-6 trans-signaling [23],
`whereas signaling via the membrane-bound IL-6R is referred to as
`classic signaling [18] (Fig. 1A). The complex of IL-6 and sIL-6R can
`stimulate all cells of the body and thereby mimic signals from
`other cytokines of the IL-6 family [5]. Interestingly, IL-6 trans-
`signaling is mimicked by the viral ortholog of IL-6 (vIL-6) encoded
`by the human herpes virus 8 (HHV8), which directly binds to and
`stimulates gp130 and does not depend on IL-6R [24,25].
`In
`principle, the soluble forms of the other two membrane-bound a-
`receptors CNTFR and IL-11R can also form biologically active
`soluble complexes, CNTF/sCNTFR [26] and IL-11/sIL-11R [27]. It is,
`however, unlikely that trans-signaling of CNTF and IL-11 via
`
`Lassen - Exhibit 1019, p. 2
`
`

`

`C. Garbers et al. / Cytokine & Growth Factor Reviews 23 (2012) 85–97
`
`87
`
`Fig. 1. Receptor complexes and major JAK/STAT signaling pathways of the IL-6-type family of cytokines. (A) All cytokines of the gp130-signaling family use gp130 (red) as at
`least one part of the signal-transducing b-receptor complex. Some cytokines need additional b-receptor molecules directly involved in signal transduction into the cell (LIF-R
`(dark orange), OSM-R (orange), WSX-1 (wheat), GPL (dark red) or non-signaling a-receptors (IL-6R (blue), IL-11-R (green), CNTF-R (dark grey), EBI3 (grey)). Cytokines of this
`family are IL-6 (dark blue), IL-11 (green), CNTF (black), CLC (black), CT-1 (grey), OSM (grey), LIF (grey), IL-27 (light grey) and IL-31 (lightest grey). CLC may require an
`additional a-receptor. The dominant STAT factor activations are marked in bold, however, this general assignment might not be true for all cells. (B) Comparison of the
`binding site II of IL-6-type cytokines IL-6, CNTF, LIF and OSM (yellow circle) and the complex of IL-6 (site II) with gp130 (cytokine binding module (CBM) domains 2–3, yellow
`circle). (C) Structure of IL-6. The binding sites of IL-6 to the IL-6R (site I) and to gp130 (site II and site III) are indicated. (D) Schematic assembly of the hexameric gp130-
`signaling complex. Sites I, II and III of IL-6 are indicated with I, II, III. Site I is in contact with IL-6R, site II with gp130-CBM and site III with gp130-Ig (D1).
`
`sCNTFR and sIL-11R is relevant in vivo, since no naturally occurring
`sCNTFR and sIL-11R were found so far. On the other hand, IL-30
`signals as composite cytokine IL-27 only via the trans-signaling
`mechanism, since EBI3 is only expressed as a soluble protein.
`It was shown that a soluble form of gp130 (sgp130) is the
`natural
`inhibitor of
`IL-6 trans-signaling
`[28,29]. Therefore,
`recombinant sgp130 is used as a molecular tool to distinguish
`between classic- and trans-signaling. IL-6 is known to exhibit pro-
`inflammatory and regenerative activities [30]. For example, IL-6/
` mice are more susceptible in an inflammatory bowel disease
`model as compared to wild type mice [31] but protected in mouse
`models of rheumatoid arthritis [32,33]. It turned out that for pro-
`inflammatory signals,
`IL-6 acts via the sIL-6R whereas the
`regenerative activities of IL-6 and the induction of the hepatic
`acute-phase response are induced via the membrane-bound IL-6R
`[30]. This has led to the evaluation of an Fc-fusion protein of
`sgp130 (sgp130Fc) as a therapeutic principle to neutralize the
`
`pro-inflammatory activities of IL-6, which would not compromise
`other beneficial activities of IL-6 [34,35]. Importantly, sgp130Fc
`does not inhibit the signaling of the other IL-6-type cytokines [36].
`First clinical trials with the sgp130Fc protein are planned for 2012.
`Despite a molar excess of sIL-6R over IL-6, free IL-6 and IL-6 in IL-6/
`sIL-6R complexes are present which allows both classic and trans-
`signaling. Under these conditions, sgp130 was, however, able to
`trap all free IL-6 molecules in IL-6/sIL-6R/sgp130 complexes,
`resulting in inhibition of classic signaling by sgp130 [37].
`Finally, binding of IL-6-type cytokines to signal-transducing
`transmembrane b-receptors induces the activation of receptor-
`bound Janus kinases (JAKs) and subsequent signaling pathways
`including signal transducers and activators of transcription (STAT)
`transcription factors, mitogen-activated protein kinases (MAPK),
`in particular the extracellular signal regulated kinases (Erk1/2),
`and phosphoinositide 3-kinase (PI3K). Several control mechanisms
`and negative
`feedback regulators are
`limiting
`IL-6 signaling
`
`Lassen - Exhibit 1019, p. 3
`
`

`

`88
`
`C. Garbers et al. / Cytokine & Growth Factor Reviews 23 (2012) 85–97
`
`pathways at different levels, including receptor internalization,
`expression of suppressors of cytokine signaling proteins (SOCS),
`the action of protein inhibitors of activated STATs (PIAS) and
`protein tyrosine phosphatases (PTP). For a detailed description of
`intracellular signaling of IL-6-type cytokines, we recommend the
`review article by Heinrich et al. [6].
`
`3. Plasticity and intra-familiar cross-talk of IL-6-type cytokines
`
`The well-documented plasticity of gp130 as common b-chain
`receptor of IL-6-type cytokines is not the only example of receptor
`cross-talk within the IL-6 family. OSM can signal via two different
`pairs of b-receptors, namely LIFR/gp130 (type I) and OSMR/gp130
`(type II) [6], which broadens the spectrum of cells that can be
`activated by OSM. This feature seems to be restricted to human OSM,
`since in mice, OSM exhibits only high affinity for the heterodimeric
`receptor pair OSMR/gp130 [38,39]. Interestingly, ongoing studies
`indicate that rat OSM resembles human OSM in signaling via both
`type I and type II receptor complexes (own unpublished results,
`H.M.H.). Plasticity is not restricted to cytokine/b-chain receptor
`interaction. The IL-6R can also interact with different ligands.
`Besides IL-6 [30], the IL-6R was shown to bind to CNTF, albeit at
`lower affinity compared to CNTF/CNTFR interaction. The CNTF/IL-6R
`complex was able to induce the formation of a heterodimer of
`gp130/LIFR for the activation of signal transduction [40] (Fig. 2).
`Another ligand for the IL-6R was recently shown to be IL-30, the IL-
`27 cytokine subunit p28 [41] (Fig. 2). The binding of IL-30 to IL-6R
`leads to
`plus assembly of the b-receptor signaling complex
`activation and phosphorylation of STAT1 and STAT3. Like in the
`case of CLC, the cytokine-like factor-1 (CLF) was needed for efficient
`secretion of IL-30, but not for signaling. During formation of the b-
`receptor signaling complex, CLF is replaced by one of the b-
`receptors. CLF interacts with site III of the cytokines CLC and IL-30. In
`the case of CLC, CLF is replaced by the LIFR upon formation of the
`signaling competent ternary receptor complex [42]. For IL-30, the
`common architecture of the cytokine/b-receptor complex is not
`possible in which site II interacts with CBM of gp130 and site III the
`Ig-like domain of LIFR or OSMR or a second gp130 in case of gp130
`homodimer
`formation. As a consequence,
`IL-27
`(IL-30/EBI3)
`interacts with gp130 via site III and with WSX-1 via site II.
`Therefore, in the case of IL-30/CLF, CLF must be replaced by gp130
`during b-receptor complex formation. The receptor composition of
`IL-30/IL-6R has not been identified [41]. The proposed gp130/WSX1
`heterodimer seemed to be likely, but was recently challenged [43].
`The authors demonstrate that the beneficial effects of IL-30 in the
`treatment of liver injury also occur in WSX-1-deficient mice, making
`the signaling via a gp130/WSX-1 heterodimer impossible. Therefore,
`the signal-transducing b-receptors for IL-30/IL-6R remains to be
`
`determined (Fig. 2). In IL-6 trans-signaling, IL-6 can induce signaling
`via the soluble IL-6R [23,44]. Interestingly, CNTF can also form a
`biologically active complex with sIL-6R but a naturally occurring
`sCNTFR was not described so far (Fig. 2) [40]. It remains to be shown,
`whether IL-30 is also able to form a biologically active composite
`cytokine with the sIL-6R (Fig. 2). This is of importance, since in
`humans about 30–50 ng/ml sIL-6R are present in the circulation. In
`pathophysiological conditions sIL-6R levels rise 2–3fold. Whether
`the biological activity of CNTF/sIL-6R and IL-30/sIL-6R complexes
`would be inhibited by sgp130 was not investigated.
`Since gp130 shows a remarkable plasticity by integrating the
`binding of all IL-6-type cytokines to a single b-receptor, specific
`differences between the signal transduction of IL-6-type cytokines
`must be determined not only by receptor expression pattern but
`also by the accompanying second b-receptor chain. However, since
`some cytokines use the same homo- or heterodimeric receptor
`complexes such as IL-6 and IL-11 or LIF, CNTF, OSM, CLC and CT-1,
`it is still not clear whether the intracellular signaling of these
`cytokines is identical or if the signal transduction of the same b-
`receptor complex is different with respect to the cytokine bound.
`Moreover, it has to be stated that, although the described cross-talk
`of cytokines and cytokine receptors leads to multiple possible
`combination of active b-receptor complexes, cytokine binding
`mainly results in the activation of only a few major signaling
`pathways, which include the aforementioned STAT, MAPK and
`PI3K proteins. It is not clear how this is regulated in space and time
`for dynamic signal transduction. Even though the plasticity of
`cytokine/cytokine receptor interactions is the basis for the broad
`IL-6-type cytokine redundancy, differences in their signal trans-
`duction should be expected and were indeed demonstrated [45].
`
`4. IL-35: the first shared IL-6/IL-12 family cytokine
`
`is a
`family
`IL-6
`the
`latest discovered cytokine of
`The
`heterodimer composed of p35 (cytokine subunit of IL-12) and
`IL-27).
`IL-35 was discovered by
`EBI3 (a-receptor subunit of
`Collison et al. [46], although the ability of the two proteins to form
`a complex and to be secreted together from cells was already
`demonstrated ten years before [47]. IL-35 bridges the IL-6 and the
`IL-12 cytokine families. The IL-12 family consists of the two
`heterodimers IL-12 (p35/p40; cytokine/a-receptor) [48] and IL-23
`(p19/p40) [49]. IL-35 it is the first shared member of the two
`cytokine families and defines an inter-familiar cross-talk (Fig. 3).
`The recently
`identified b-receptors and the specific STAT
`proteins activated by IL-35 are unconventional [50]. IL-35 signals
`via three different pairs of b-receptors, a gp130 homodimer, an
`IL-12Rb2 homodimer or
`a
`gp130/IL-12Rb2 heterodimer.
`Whereas IL-35-induced gp130 homodimer formation leads to
`
`CNTF
`
`
`
`IL-3
`
`0 (p28)
`
`?
`
`CNTFRCNTFR
`
`gp130/LIFR
`
`
`High
`affinity
`
`IL 6RIL-6R
`
`gp130/LIFR
`
`
`sIL 6RsIL-6R
`
`gp130/LIFR
`
`Low
`affinity
`
`
`EBI3EBI3
`
`
`gp130/WSX-1
`
`High
`affinity
`
`IL 6RIL-6R
`
`gp130/?
`
`sIL 6RsIL-6R
`
`gp130/?
`
`Low
`affinity
`
`Fig. 2. Plasticity and intra-familiar cross-talk of CNTF and IL-30. CNTF binds to CNTFR (high affinity) and to membrane-bound and soluble IL-6R (low affinity). IL-30 binds to
`EBI3 (high affinity) and to membrane-bound IL-6R and very likely also to the soluble IL-6R. The receptor combination of IL-30/IL-6R might be the same as for IL-27 (IL-30/
`EBI3).
`
`Lassen - Exhibit 1019, p. 4
`
`

`

`C. Garbers et al. / Cytokine & Growth Factor Reviews 23 (2012) 85–97
`
`89
`
`IL-27
`
`IL-35
`
`EBI3
`
`IL-30
`
`
`(p28)(p )
`
`
`(IL-12A)( )
`
`
`
`p35
`
`
`
`
`EBI3
`
`IL-12
`
`p35
`
`(IL-12A)(IL 12A)
`
`p40
`
`X-1
`
`gp130/WS
`
`STAT1/
`STAT3/
`STAT5
`
`gp130/gp130
`
`
`
`STAT1
`
`gp130/IL-12Rβ2
`
`
`
`STAT1/
`STAT4
`
`IL-12Rβ2/IL-1
`2Rβ2
`
`STAT4
`
`IL-12Rβ2/IL-12Rβ1
`
`
`
`STAT1/
`STAT3/
`STAT4/
`STAT5
`
`Fig. 3. Receptor composition of the novel IL-6/IL-12 cytokine IL-35. IL-35 binds to and activates three different combinations of receptor complexes, a gp130 homodimer
`(STAT1), a gp130/IL-12Rb2 heterodimer (STAT1/STAT4) and an IL-12Rb2 homodimer (STAT4). For comparison the receptor composition of IL-27 and IL-12 plus main STAT
`factors is given.
`
`the phosphorylation/activation of STAT1, the IL-12Rb2 homodimer
`phosphorylates only STAT4 and the gp130/IL-12Rb2 heterodimer
`phosphorylates both STAT1 and STAT4 leading to the formation of
`phosphorylated STAT1/STAT4 heterodimers (Fig. 3). Since IL-35 is
`composed of subunits from IL-12 and IL-27, it is not surprising that
`also the b-receptors are shared between the families, but the use of
`three different receptor pairings, resulting in the recruitment and
`activation of three different and distinct STAT proteins or STAT
`protein combinations, makes IL-35 a special family member. These
`findings furthermore underline the complex network of cytokine
`subunits and membrane-bound a- and b-receptors that are engaged
`in different combinations to induce biological actions. Since gp130
`homodimer formation after IL-6 or IL-11 binding leads to the strong
`tyrosine phosphorylation of STAT3 and a weaker STAT1 activation, it
`is not trivial to imagine how the same gp130 homodimer after
`binding of IL-35 leads to STAT1 but not to STAT3 phosphorylation.
`Keeping this in mind, a comprehensive comparison of IL-35-, IL-6-
`and IL-11-induced gp130 homodimer formation and signal trans-
`duction will help to unravel the basis of differential signal
`transduction from the same b-receptor complex depending on
`the bound cytokine. It can be speculated that binding of the different
`cytokines to the same receptor complex results
`in different
`orientations which might give access only to a specific set of
`tyrosine motifs in the intracellular region [51].
`Extensive cross-talk and sharing of subunits and receptors
`makes it difficult to address the biological functions of the different
`cytokines in vivo. In the case of IL-35, neither EBI3-deficient nor
`p35-deficient mice represent solely IL-35-deficiency, because EBI3
`is also involved in IL-27 signaling and p35 in IL-12 signaling.
`Therefore the reassignment of data achieved from these mice to
`the function of a single cytokine is impossible. One alternative
`strategy might be to compare p35- with p40-deficient mice. Both
`knock-out mice lack IL-12 signaling, but only p35-deficient mice
`additionally lack IL-35. Unfortunately, also interpretation of data
`from these animal experiments is complicated by cytokine subunit
`cross-talk, since p40 is shared between IL-12 [48] and IL-23 [49],
`making p40-deficient mice unresponsive to both cytokines. Finally,
`also the comparison of EBI3-deficient mice with IL-30-deficient
`mice is not helpful. Several reports have shown that IL-30 has
`functions independently of IL-27 [41,52,53], although the available
`data are conflicting. Shimozato et al. [53] reported that IL-30 alone
`can inhibit IL-27-mediated signaling, whereas Stumhofer et al. [52]
`identified
`IL-30 as a general antagonist of gp130-mediated
`signaling. In contrast, Crabe et al. [41] found that IL-30 is able
`to signal via the IL-6R. The latest report by Dibra et al. [43]
`underlines the agonistic signaling capacities of
`IL-30. They
`
`characterize IL-30 as an anti-inflammatory cytokine capable of
`inhibiting
`inflammation-induced
`liver
`injury, an ability not
`executed by IL-27 (IL-30/EBI3). To date it is unclear how these
`different findings can be included into one model of IL-30 action,
`but it is clear that the listed IL-30 functions, which are independent
`of EBI3, are also absent in IL-30-deficient mice. This makes it
`impossible to dissect the role of IL-35 in vivo by comparing EBI3-
`deficient with IL-30-deficient mice.
`In summary, it is currently not possible to generate conclusive
`IL-35-deficient mice and even data from the aforementioned
`knock-out animals of IL-30, EBI3, p40 have to be interpreted with
`caution due to intensive cytokine/cytokine receptor cross-talk.
`Presenting EBI3-deficient mice as IL-35-deficient mice [55] is
`misleading, since the in vivo roles of IL-35 cannot be dissected from
`IL-27. Time will
`tell whether sophisticated mouse-genetic
`approaches or
`the use of
`inhibitory antibodies, specifically
`targeting the EBI3:p35 heterodimer, will give rise to meaningful
`IL-35-deficient mice.
`Already in 1993, the shared IL-12/IL-23 subunit p40 has been
`shown to be able to inhibit signaling of IL-12 [56]. Later reports
`have proven the existence and antagonistic properties of an IL-
`12p40 homodimer, named IL-12p80 [57,58]. This homodimer is
`able to bind to the IL-12Rb1, thereby antagonizing IL-12-mediated
`signaling by inhibiting binding of IL-12 to its receptor, without
`mediating biologic activities on its own [59]. In vivo, up to one-
`third of the total amount of p40 has been shown to exist as dimeric
`p80 [60]. IL-12p40 can also inhibit IL-23 mediated signaling,
`because IL-23 signals via a heterodimer of IL-12Rb1 and IL-23R.
`[61]. The inhibitory actions of p80 might also contribute to the
`phenotypes seen in p35 and p40-deficient mice, again complicat-
`ing the generation of IL-35-deficient mice.
`Here, we have summarized cross-talk of the extracellular
`signaling network of cytokines, cytokine subunits and soluble
`receptors of the IL-6/IL-12 family. It is tempting to speculate
`that future work will unravel additional roles of single subunits,
`novel heterodimeric cytokines and agonistic or antagonistic
`functions of soluble cytokine receptors. Moreover, less attention
`was paid to the species specificity, since it is not clear whether
`the plasticity of cytokine receptor assembly within the IL-6/IL-
`12 family is the same in men, rats or mice. This is exemplified by
`differences for human and murine OSM [38,39] and by rat CNTF
`which is able to engage signaling via a heterodimer of gp130/
`LIFR in the absence of CNTFR [62], a feature that has not been
`observed for murine or human CNTF. Therefore, one has to be
`cautious with the transfer of findings from mice or rats to the
`human situation.
`
`Lassen - Exhibit 1019, p. 5
`
`

`

`90
`
`C. Garbers et al. / Cytokine & Growth Factor Reviews 23 (2012) 85–97
`
`5. Inter-familiar cross-talk of the major early pro-inflammatory
`cytokines IL-6, IL-1 and TNFa
`
`The duration and strength of IL-6-type cytokine-mediated
`signaling is tightly regulated to avoid overshooting pro-inflamma-
`tory activities. However, also anti-inflammatory activities have to
`be restricted since premature termination of the inflammatory
`response might prevent efficient anti-bacterial or regenerative
`activities.
`In the past decade much attention has been paid on the cross-
`talk elicited by the pro-inflammatory cytokines, IL-1b and TNFa
`with IL-6. Two important proteins were identified as critical
`regulators
`to
`influence
`IL-6-mediated signaling:
`the serine/
`threonine protein kinase p38, a stress-activated MAPK, and the
`transcription factor NF-kB (Fig. 4).
`The liver is one of the most important organs responding to IL-6
`[63]. IL-6 is crucial for the induction of hepatic class I and class II
`acute-phase gene expression and the regeneration of the liver after
`partial hepatectomy. These mechanisms are fundamental to cope
`with infections, toxic stress and traumata [64–66]. Already in the
`late 1980s it was recognized that IL-1b exerts a strong suppressive
`activity on the class II acute-phase protein release initiated by IL-6
`[67]. This complex species- as well as tissue-specific suppressive
`activity depends on at least two activities of IL-1b. An immediately
`acting reduction/prevention of the IL-6-induced STAT3 tyrosine
`phosphorylation [22,68,69] and delayed effects influencing either
`the binding of STAT3 to promoters of target genes or the prolonged
`STAT3 activation [70–72]. The rapid inhibition of early STAT3
`tyrosine phosphorylation was shown to be independent of protein
`de novo synthesis, the activity of tyrosine phosphatases and NF-kB
`activation; however, it required the activity of p38 MAPK [22,69].
`
`Pro-inflammatory cytokines can directly impact on the cell
`surface expression of gp130. It has been shown that gp130
`expression on human primary smooth muscle cells [73] and on
`mast cells [74] can be reg

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket